Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data

Key Points

• Healthcare utilization is notably high in dermatomyositis patients, indicating a significant burden on the healthcare system.
• Data reveals substantial glucocorticoid exposure among those diagnosed with dermatomyositis, emphasizing treatment challenges.
• Observational analysis of administrative claims and EHR data examines treatment patterns and outcomes in dermatomyositis cohorts.
• Findings suggest heterogeneity in treatment approaches, which may impact patient outcomes and overall disease management.